Company Encyclopedia
View More
name
Aidea Pharma
688488.SH
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products.
1.601 T
688488.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking44/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-8.51%D
    • Profit Margin-12.97%D
    • Gross Margin67.51%A
  • Growth ScoreB
    • Revenue YoY64.27%A
    • Net Profit YoY16.69%B
    • Total Assets YoY-4.32%D
    • Net Assets YoY-6.13%D
  • Cash ScoreC
    • Cash Flow Margin-770.73%E
    • OCF YoY64.27%A
  • Operating ScoreD
    • Turnover0.36D
  • Debt ScoreC
    • Gearing Ratio41.35%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aidea Pharma: Sodium Dolutegravir API receives approval for listing application

    Aidea Pharma's wholly-owned subsidiary, Yangzhou Aidea Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration to market the active pharmaceutical ingredient of Multilavir Sodium. This drug is used for the treatment of HIV infection and is suitable for adults and children over 12 years old. This approval will enhance the supply and quality of the active pharmaceutical ingredient, reduce production costs, and strengthen the company's competitiveness, but it is expected to have no significant impact on recent operations

    Zhitong·
    SH
    688488
    -2.11%
    Zhitong·
    SH
    688488
    -2.11%

    Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine

    Aidea Pharma announced on October 11th that the results of its self-developed anti-HIV drug Fubangde® SPRINT's Phase III clinical study have been published in BMC Medicine. This journal is a top medical journal with an impact factor of 9.4, and the influence of the published research results surpasses that of imported similar products

    Zhitong·
    SH
    688488
    -2.11%
    Zhitong·
    SH
    688488
    -2.11%

    Aidea Pharma: Ainomit Tablets Obtains Drug Registration Certificate in Zanzibar

    Aidea Pharma recently obtained the Drug Registration Certificate for Ainomi Tablets issued by the Zanzibar Food and Drug Authority. This drug is a compound anti-HIV-1 infection chemical drug developed independently by the company, based on the novel non-nucleoside reverse transcriptase inhibitor Ainovelin Tablets, which includes two nucleoside reverse transcriptase inhibitors: fumarate tenofovir disoproxil and lamivudine

    Zhitong·
    SH
    688488
    -2.11%
    Zhitong·
    SH
    688488
    -2.11%

    New regulations for national HIV drug resistance research released, Aidea Pharma deeply involved

    Aidea Pharma participated in the "Guidelines for Clinical Drug Resistance Research and Data Submission for Anti-HIV Infection" released by the National Medical Products Administration, providing regulatory support for the research and development of anti-HIV drugs. The company was invited to attend a relevant expert consultation meeting in September 2024, demonstrating its leadership position in the domestic anti-HIV research and development field

    Wallstreetcn·
    SH
    688488
    -2.11%
    Wallstreetcn·
    SH
    688488
    -2.11%

    Aidea Pharma plans to launch a stock option incentive plan for 11.375 million shares

    According to the Zhitong Finance APP, Aidea Pharma disclosed its 2025 stock option incentive plan (draft), proposing to grant a total of 11.375 million stock options, accounting for approximately 2.703% of the company's total equity at the time of the announcement of the incentive plan draft. Among them, 9.1 million options will be granted initially, with a total of 45 individuals as the initial grantees, and the exercise price is set at 13.01 yuan per option

    Zhitong·
    SH
    688488
    -2.11%
    Zhitong·
    SH
    688488
    -2.11%